180 related articles for article (PubMed ID: 8997630)
1. Iloperidone binding to human and rat dopamine and 5-HT receptors.
Kongsamut S; Roehr JE; Cai J; Hartman HB; Weissensee P; Kerman LL; Tang L; Sandrasagra A
Eur J Pharmacol; 1996 Dec; 317(2-3):417-23. PubMed ID: 8997630
[TBL] [Abstract][Full Text] [Related]
2. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone.
Subramanian N; Kalkman HO
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Apr; 26(3):553-60. PubMed ID: 11999907
[TBL] [Abstract][Full Text] [Related]
3. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.
Szewczak MR; Corbett R; Rush DK; Wilmot CA; Conway PG; Strupczewski JT; Cornfeldt M
J Pharmacol Exp Ther; 1995 Sep; 274(3):1404-13. PubMed ID: 7562515
[TBL] [Abstract][Full Text] [Related]
4. Conformationally constrained butyrophenones with affinity for dopamine (D(1), D(2), D(4)) and serotonin (5-HT(2A), 5-HT(2B), 5-HT(2C)) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics.
Raviña E; Casariego I; Masaguer CF; Fontenla JA; Montenegro GY; Rivas ME; Loza MI; Enguix MJ; Villazon M; Cadavid MI; Demontis GC
J Med Chem; 2000 Nov; 43(24):4678-93. PubMed ID: 11101359
[TBL] [Abstract][Full Text] [Related]
5. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
Leysen JE; Janssen PM; Megens AA; Schotte A
J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
[TBL] [Abstract][Full Text] [Related]
6. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders.
Kalkman HO; Subramanian N; Hoyer D
Neuropsychopharmacology; 2001 Dec; 25(6):904-14. PubMed ID: 11750183
[TBL] [Abstract][Full Text] [Related]
7. 3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873).
Strupczewski JT; Bordeau KJ; Chiang Y; Glamkowski EJ; Conway PG; Corbett R; Hartman HB; Szewczak MR; Wilmot CA; Helsley GC
J Med Chem; 1995 Mar; 38(7):1119-31. PubMed ID: 7707315
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity.
Szczepanik AM; Brougham LR; Roehr JE; Conway PG; Ellis DB; Wilmot CA
J Pharmacol Exp Ther; 1996 Aug; 278(2):913-20. PubMed ID: 8768747
[TBL] [Abstract][Full Text] [Related]
9. In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors.
Hidaka K; Tada S; Matsumoto M; Ohmori J; Tasaki Y; Nomura T; Usuda S; Yamaguchi T
Br J Pharmacol; 1996 Apr; 117(8):1625-32. PubMed ID: 8732269
[TBL] [Abstract][Full Text] [Related]
10. [The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors].
Futamura T; Ohashi Y; Yano K; Takahashi Y; Haga K; Fukuda T
Nihon Yakurigaku Zasshi; 1996 May; 107(5):247-53. PubMed ID: 8690306
[TBL] [Abstract][Full Text] [Related]
11. The naphtosultam derivative RP 62203 (fananserin) has high affinity for the dopamine D4 receptor.
Heuillet E; Petitet F; Mignani S; Malleron JL; Lavayre J; Néliat G; Doble A; Blanchard JC
Eur J Pharmacol; 1996 Oct; 314(1-2):229-33. PubMed ID: 8957240
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors.
Kalkman HO; Feuerbach D; Lötscher E; Schoeffter P
Life Sci; 2003 Jul; 73(9):1151-9. PubMed ID: 12818723
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and binding affinity of potential atypical antipsychotics with the tetrahydroquinazolinone motif.
Carro L; Raviña E; Domínguez E; Brea J; Loza MI; Masaguer CF
Bioorg Med Chem Lett; 2009 Nov; 19(21):6059-62. PubMed ID: 19796944
[TBL] [Abstract][Full Text] [Related]
14. From anti-allergic to anti-Alzheimer's: Molecular pharmacology of Dimebon.
Okun I; Tkachenko SE; Khvat A; Mitkin O; Kazey V; Ivachtchenko AV
Curr Alzheimer Res; 2010 Mar; 7(2):97-112. PubMed ID: 19939222
[TBL] [Abstract][Full Text] [Related]
15. Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?
Albers LJ; Musenga A; Raggi MA
Expert Opin Investig Drugs; 2008 Jan; 17(1):61-75. PubMed ID: 18095919
[TBL] [Abstract][Full Text] [Related]
16. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
17. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease.
Scheller D; Ullmer C; Berkels R; Gwarek M; Lübbert H
Naunyn Schmiedebergs Arch Pharmacol; 2009 Jan; 379(1):73-86. PubMed ID: 18704368
[TBL] [Abstract][Full Text] [Related]
18. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes.
Lawler CP; Prioleau C; Lewis MM; Mak C; Jiang D; Schetz JA; Gonzalez AM; Sibley DR; Mailman RB
Neuropsychopharmacology; 1999 Jun; 20(6):612-27. PubMed ID: 10327430
[TBL] [Abstract][Full Text] [Related]
19. Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone.
Mutlib AE; Klein JT
J Pharmacol Exp Ther; 1998 Sep; 286(3):1285-93. PubMed ID: 9732390
[TBL] [Abstract][Full Text] [Related]
20. Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in vitro and in vivo metabolites of iloperidone.
Mutlib AE; Strupczewski JT; Chesson SM
Drug Metab Dispos; 1995 Sep; 23(9):951-64. PubMed ID: 8565786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
